Sex-by-formulation interaction in bioequivalence trials with transdermal patches
- 7 Downloads
The existence of a sex-by-formulation interaction in bioequivalence studies implies that the bioequivalence results (i.e., the test/reference ratio of the pharmacokinetic parameters) obtained in one sex are not similar to those obtained in the other sex. Therefore, results obtained in studies including only males may not be representative of the results obtained in females and vice versa. The best evidence of the existence of a sex-by-formulation interaction has been obtained from a study conducted with transdermal patches. This observation might be caused by the different characteristics of the skin of males and females. The purpose of this work is to investigate the existence of a sex-by-formulation interaction in all bioequivalence studies of transdermal patches submitted to the Spanish Agency for Medicines between 2010 and 2016.
Only five different products (Buprenorphine-1, Fentantyl-1, Fentanyl-2, Rivastigmine-1 and Rivastigmine-2) that were submitted for registration included nine bioequivalence studies conducted in males and females. As single dose and multiple dose studies are required for registration of transdermal patches in the European Union, more than one study may be available to confirm the existence of a sex-by-formulation interaction.
A sex-by-formulation interaction is suggested in six out of 27 datasets (22%), corresponding to two products, and it is statistically significant in three of them (11%).
The sex-by-formulation interaction detected in some pharmacokinetic parameters of some studies is excluded when the study is repeated, which shows that these results are not reproducible. There is no evidence to require bioequivalence demonstration for transdermal patches in males and females separately.
KeywordsSex-by-formulation interaction Bioequivalence Transdermal patches Males Females
The authors are grateful to Mr. Jesús Garrido for his assistance in the statistical analysis.
A.G.-A., J.G. and E.G.-R. contributed to the conception of the work and the interpretation of the results. A.G.-A. and S.M. contributed in the acquisition of the data of the bioequivalence studies of transdermal patches submitted to the Spanish Agency for Medicines and Health Care Products. E.G.-R., J.M., F.A-S. and C.Á. conducted the analysis of the data.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.European Medicines Agency. Guideline on the investigation of bioequivalence. London, 2′ January 2010. CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. (Accessed 29.04.2017).
- 3.U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability and Bioequivalence. Studies for Orally Adminsitered Drug Products - General Considerations. March 2003, revision 1. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf. (Accessed 29.04.2017)
- 4.González-Rojano E, Abad-Santos F, Ochoa D, Román M, Marcotegui J, Álvarez C, Gordon J, García-Arieta A (2018) Evaluation of sex-by-formulation interaction in bioequivalence studies of efavirenz tablets. Br J Clin Pharmacol 84(8):1729–1737. https://doi.org/10.1111/bcp.13601 CrossRefPubMedGoogle Scholar
- 5.Chen ML, Lee SC, Ng MJ, Schuirmann DJ, Lesko LJ, Williams RL (2000) Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 68(5):510–521. https://doi.org/10.1067/mcp.2000.111184. CrossRefPubMedGoogle Scholar
- 9.García-Arieta A, Morales-Alcelay S, Herranz M, de la Torre-Alvarado JM, Blázquez-Pérez A, Suárez-Gea ML, Alvarez C (2012) Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products. Int J Pharm 423(2):321–325. https://doi.org/10.1016/j.ijpharm.2011.11.022. CrossRefPubMedGoogle Scholar
- 12.European Medicines Agency. Guideline on the investigation of subgroups in confirmatory clinical trials (draft), 23 January 2014. EMA/CHMP/539146/2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500160523.p. Accessed 29 April 2017